Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study

BCR-ABL kinase domain inhibition can be used to treat chronic myeloid leukemia. The inhibitors such as imatinib, dasatinib and nilotinib are effective drugs but are resistant to some BCR-ABL mutations. The pan-BCR-ABL kinase inhibitor ponatinib exhibits potent activity against native, T315I, and all...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanneeru, Karunakar, Guruprasad, Lalitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827254/
https://www.ncbi.nlm.nih.gov/pubmed/24236021
http://dx.doi.org/10.1371/journal.pone.0078556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827254/
https://www.ncbi.nlm.nih.gov/pubmed/24236021
http://dx.doi.org/10.1371/journal.pone.0078556

Ejemplares similares